Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review

Sydney Rosen, Matthew P Fox, Christopher J Gill, Sydney Rosen, Matthew P Fox, Christopher J Gill

Abstract

Background: Long-term retention of patients in Africa's rapidly expanding antiretroviral therapy (ART) programs for HIV/AIDS is essential for these programs' success but has received relatively little attention. In this paper we present a systematic review of patient retention in ART programs in sub-Saharan Africa.

Methods and findings: We searched Medline, other literature databases, conference abstracts, publications archives, and the "gray literature" (project reports available online) between 2000 and 2007 for reports on the proportion of adult patients retained (i.e., remaining in care and on ART) after 6 mo or longer in sub-Saharan African, non-research ART programs, with and without donor support. Estimated retention rates at 6, 12, and 24 mo were calculated and plotted for each program. Retention was also estimated using Kaplan-Meier curves. In sensitivity analyses we considered best-case, worst-case, and midpoint scenarios for retention at 2 y; the best-case scenario assumed no further attrition beyond that reported, while the worst-case scenario assumed that attrition would continue in a linear fashion. We reviewed 32 publications reporting on 33 patient cohorts (74,192 patients, 13 countries). For all studies, the weighted average follow-up period reported was 9.9 mo, after which 77.5% of patients were retained. Loss to follow-up and death accounted for 56% and 40% of attrition, respectively. Weighted mean retention rates as reported were 79.1%, 75.0% and 61.6 % at 6, 12, and 24 mo, respectively. Of those reporting 24 mo of follow-up, the best program retained 85% of patients and the worst retained 46%. Attrition was higher in studies with shorter reporting periods, leading to monthly weighted mean attrition rates of 3.3%/mo, 1.9%/mo, and 1.6%/month for studies reporting to 6, 12, and 24 months, respectively, and suggesting that overall patient retention may be overestimated in the published reports. In sensitivity analyses, estimated retention rates ranged from 24% in the worse case to 77% in the best case at the end of 2 y, with a plausible midpoint scenario of 50%.

Conclusions: Since the inception of large-scale ART access early in this decade, ART programs in Africa have retained about 60% of their patients at the end of 2 y. Loss to follow-up is the major cause of attrition, followed by death. Better patient tracing procedures, better understanding of loss to follow-up, and earlier initiation of ART to reduce mortality are needed if retention is to be improved. Retention varies widely across programs, and programs that have achieved higher retention rates can serve as models for future improvements.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1. Study Flow Chart
Figure 1. Study Flow Chart
Figure 2. Attrition Rates by Reporting Duration
Figure 2. Attrition Rates by Reporting Duration
(A) Studies reporting to 6 mo median follow-up. (B) Studies reporting to 12 mo median follow-up. (C) Studies reporting to 24 mo median follow-up. (D) Weighted mean attrition rates by duration cohort. SA, South Africa.
Figure 3. Sensitivity Analysis for Attrition
Figure 3. Sensitivity Analysis for Attrition

References

    1. Mills EJ, Nachega JB, Buchan I, Orbinski J, Attaran A, et al. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA. 2006;296:679–690.
    1. Akileswaran C, Lurie MN, Flanigan TP, Mayer KH. Lessons learned from use of highly active antiretroviral therapy in Africa. Clin Infect Dis. 2005;41:376–385.
    1. Gill CJ, Hamer D, Simon JL, Thea DM, Sabin L. No room for complacency about adherence to antiretroviral therapy in sub-Saharan Africa. AIDS. 2005;19:1243–1249.
    1. Mocroft AJ, Lundgren JD, d'Armino MA, Ledergerber B, Barton SE, et al. Survival of AIDS patients according to type of AIDS-defining event. Int J Epidemiol. 1997;26:400–407.
    1. Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boulle A, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet. 2006;367:817–824.
    1. Ivers LC, Kendrick D, Doucette K. Efficacy of antiretroviral therapy programs in resource-poor settings: a meta-analysis of the published literature. Clin Infect Dis. 2005;41:217–224.
    1. Morgan D, Mahe C, Mayanja B, Okongo JM, Lubega R, et al. HIV-1 infection in rural Africa: is there a difference in median time to AIDS and survival compared with that in industrialized countries? AIDS. 2002;16:597–603.
    1. Sabate E. Adherence to long-term therapies: evidence for action. Geneva: World Health Organization; 2003. Available: . Accessed 25 July 2007.
    1. World Health Organization. Global tuberculosis control—surveillance, planning, financing. WHO Report 2007. Geneva: World Health Organization; 2007. 2007. Report No. WHO/HTM/TB/2007.376. Available: . Accessed 2 August 2007.
    1. Hosseinipour MC, Neuhann FH, Kanyama CC, Namarika DC, Weigel R, et al. Lessons learned from a paying antiretroviral therapy service in the public health sector at kamuzu central hospital, Malawi: 1-year experience. J Int Assoc Physicians AIDS Care. 2006;5:103–108.
    1. Stringer JS, Zulu I, Levy J, Stringer EM, Mwango A, et al. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA. 2006;296:782–793.
    1. Kwong-Leung Yu J, Chih-Cheng Chen S, Wang K, Chang C, Makombe S, et al. True outcomes for patients on antiretroviral therapy who are “lost to follow-up” in Malawi. Bull World Health Organ. 2007;85:550–554.
    1. Mills EJ, Nachega JB, Bangsberg DR, Singh S, Rachlis B, et al. Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Medicine. 2006;3:e438. doi: .
    1. Weiser S, Wolfe W, Bangsberg D, Thior I, Gilbert P, et al. Barriers to antiretroviral adherence for patients living with HIV infection and AIDS in Botswana. J Acquir Immune Defic Syndr. 2003;34:281–288.
    1. Hardon AP, Akurut D, Comoro C, Ekezie C, Irunde HF, et al. Hunger, waiting time and transport costs: time to confront challenges to ART adherence in Africa. AIDS Care. 2007;19:658–665.
    1. Egger M, May M, Chene G, Phillips AN, Ledergerber B, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet. 2002;360:119–129.
    1. Hogg RS, Yip B, Chan KJ, Wood E, Craib KJ, et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA. 2001;286:2568–2577.
    1. Lawn SD, Myer L, Harling G, Orrell C, Bekker LG, et al. Determinants of mortality and nondeath losses from an antiretroviral treatment service in South Africa: implications for program evaluation. Clin Infect Dis. 2006;43:770–776.
    1. Lawn SD, Myer L, Orrell C, Bekker LG, Wood R. Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design. AIDS. 2005;19:2141–2148.
    1. Lawn SD, Wood R. How can earlier entry of patients into antiretroviral programs in low-income countries be promoted? Clin Infect Dis. 2006;42:431–432.
    1. Wester CW, Kim S, Bussmann H, Avalos A, Ndwapi N, et al. Initial response to highly active antiretroviral therapy in HIV-1C-infected adults in a public sector treatment program in Botswana. J Acquir Immune Defic Syndr. 2005;40:336–343.
    1. Bisson G, Ndwapi N, Rollins C, Avalos A, Gross R, et al. High rates of death among patients lost to follow-up in Botswana's national ART program: implications for monitoring and evaluation [abstract]; 14th Conference on Retroviruses and Opportunistic Infections (CROI);; 2007 25–28 February;; Los Angeles, California.. 2007. Abstract 537. Available: . Accessed 27 July 2007.
    1. Bisson GP, Frank I, Gross R, Lo Re V, 3rd, Strom JB, et al. Out-of-pocket costs of HAART limit HIV treatment responses in Botswana's private sector. AIDS. 2006;20:1333–1336.
    1. Laurent C, Meilo H, Guiard-Schmid JB, Mapoure Y, Noel JM, et al. Antiretroviral therapy in public and private routine health care clinics in Cameroon: lessons from the Douala antiretroviral (DARVIR) initiative. Clin Infect Dis. 2005;41:108–111.
    1. Guiard-Schmid JB, Montagut B, Ribadeau-Dumas F, Edoo G, Makong S, et al. TRICAM: Medico-economic pilot study on HAART for HIV-infected patients in a private company of Cameroon [abstract]; XVth International AIDS Conference; 2004 11–16 July;; Bangkok, Thailand: 2004. Abstract MoOrD1024.
    1. Mosoko JJ, Akam W, Weidle PJ, Brooks J, Aweh A, et al. Survival and adherence to ART in an era of decreasing drug cost in Limbe, Cameroon [abstract]; 14th Conference on Retroviruses and Opportunistic Infections (CROI);; 2007 25–28 February;; Los Angeles, California.. 2007. Abstract 536. Available: . Accessed 27 July 2007.
    1. Kenfak A, Tsague L, Koulla-Shiro S, Tejioken M, Kouanfack C, et al. Challenges in assessing adherence to antiretroviral treatment in low resources settings and impacts on national antiretroviral policy: results of a retrospective multicentric cohort study in Cameroon [abstract]; XVIth International AIDS Conference; August 14–18, 2006;; Toronto, Canada.. 2007. Abstract CDB0765.
    1. Djomand G, Roels T, Ellerbrock T, Hanson D, Diomande F, et al. Virologic and immunologic outcomes and programmatic challenges of an antiretroviral treatment pilot project in Abidjan, Cote d'Ivoire. AIDS. 2003;17((Suppl 3)):S5–15.
    1. Macharia DK, Chang LW, Lule G, Owili DM, Tesfaledet G, et al. Antiretroviral therapy in the private sector of Nairobi, Kenya: a review of the experience of five physicians. AIDS. 2003;17:938–940.
    1. Wools-Kaloustian K, Kimaiyo S, Diero L, Siika A, Sidle J, et al. Viability and effectiveness of large-scale HIV treatment initiatives in sub-Saharan Africa: experience from western Kenya. AIDS. 2006;20:41–48.
    1. Carillo de Casas E, Cox H, Ferreyra C, Isaakidis P, Mansilla C, San Miguel MJ, et al. Gender differences in a large-scale HAART program in western Kenya; XVIth International AIDS Conference;; 2006 14–18 August;; Toronto, Canada.. 2006. Abstract WEPE0243. Available: . Accessed 27 July 2007.
    1. Marston B, Macharia DK, Ng'ang'a L, Wangai M, Ilako F, et al. A program to provide antiretroviral therapy to residents of an urban slum in Nairobi, Kenya. JIAPAC. 2007;6:106–112.
    1. Karcher H, Omondi A, Odera J, Kunz A, Harms G. Risk factors for treatment denial and loss to follow-up in an antiretroviral treatment cohort in Kenya. Trop Med Int Health. 2007;12:687–694.
    1. Hawkins C, Achenbach C, Fryda W, Ngare D, Murphy R. Antiretroviral durability and tolerability in HIV-infected adults living in urban Kenya. J Acquir Immune Defic Syndr. 2007;45:304–310.
    1. Ferradini L, Jeannin A, Pinoges L, Izopet J, Odhiambo D, et al. Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet. 2006;367:1335–1342.
    1. Libamba E, Makombe S, Mhango E, de Ascurra TO, Limbambala E, et al. Supervision, monitoring and evaluation of nationwide scale-up of antiretroviral therapy in Malawi. Bull World Health Organ. 2006;84:320–326.
    1. Hosseinipour MC, Kanyama CC, Nkhalamba T, Phiri SJ, Weigel R, et al. Safety and efficacy of D4T/3TC/NVP among HIV positive adults in Lilongwe, Malawi [abstract]; XVth International AIDS Conference;; 2004 11–16 July, 2004;; Bangkok, Thailand.. 2006. Abstract TuPeB4522. Available: . Accessed 27 July 2007.
    1. Zachariah R, Teck R, Buhendwa L, Fitzerland M, Labana S, et al. Community support is associated with better antiretroviral treatment outcomes in a resource-limited rural district in Malawi. Trans R Soc Trop Med Hyg. 2007;101:79–84.
    1. Palombi L, Narciso P, Perno CF, Mancinelli S, Guidotti G, et al. One year of HAART in Mozambique: survival, virological, and immunological results of DREAM Project in adults and children [abstract]; 11th Conference on Retroviruses and Opportunistic Infections;; 2004 8–11 February;; San Francisco, California.. 2004. Abstract 148. Available: . Accessed: 27 July 2007.
    1. Etard JF, Ndiaye I, Thierry-Mieg M, Gueye NF, Gueye PM, et al. Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study. AIDS. 2006;20:1181–1189.
    1. Bekker LG, Myer L, Orrell C, Lawn S, Wood R. Rapid scale-up of a community-based HIV treatment service: programme performance over 3 consecutive years in Guguletu, South Africa. S Afr Med J. 2006;96:315–320.
    1. Charalambous S, Innes C, Muirhead D, Kumaranayake L, Fielding K, et al. Evaluation of a workplace HIV treatment programme in South Africa. AIDS. 2007;21((Suppl 3)):S73–S78.
    1. Coetzee D, Hildebrand K, Boulle A, Maartens G, Louis F, et al. Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS. 2004;18:887–895.
    1. Nachega JB, Hislop M, Dowdy DW, Lo M, Omer SB, et al. Adherence to highly active antiretroviral therapy assessed by pharmacy claims predicts survival in HIV-infected South African adults. J Acquir Immune Defic Syndr. 2006;43:78–84.
    1. Ford N, Reuter H, Bedelu M, Schneider H, Reuter H. Sustainability of long-term treatment in a rural district: the Lusikisiki model of decentralised HIV/AIDS care. Southern Afr J HIV Med. 2006;(Dec 2006):17–22.
    1. Kabugo C, Bahendeka S, Mwebaze R, Malamba S, Katuntu D, et al. Long-term experience providing antiretroviral drugs in a fee-for-service HIV clinic in Uganda: evidence of extended virologic and CD4+ cell count responses. J Acquir Immune Defic Syndr. 2005;38:578–583.
    1. Weidle PJ, Malamba S, Mwebaze R, Sozi C, Rukundo G, et al. Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance. Lancet. 2002;360:34–40.
    1. Rigon A, Nattabi B, Pido B, Pierotti C, Ojom L, et al. Evaluation of treatment outcomes and adherence among patients receiving antiretroviral therapy in the conflict-affected region of north Uganda [abstract]; XVIth International AIDS Conference; 2006 14–18 August;; Toronto, Canada.. 2006. Abstract WEPE0131.
    1. Sow PS, Otieno LF, Bissagnene E, Kityo C, Bennink R, et al. Implementation of an Antiretroviral Access Program for HIV-1-Infected Individuals in Resource-Limited Settings: Clinical Results From 4 African Countries. J Acquir Immune. 2006;44:262–267.
    1. El-Sadr W, Elul B, Rabkin M, Hawken M, Lima J, et al. Rapid expansion of HIV/AIDS care and treatment programs in 6 Sub-Saharan countries [abstract]; XVIth International AIDS Conference; 2006 14–18 August;; Toronto, Canada.. 2006. Abstract CDB1122.

Source: PubMed

3
購読する